Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported 6 hours ago - Updated 6 hours ago - 2 reports

Enzalutamide may offer chemotherapy alternative in metastatic castrationresistant prostate cancer

The United States Food and Drug Association has approved the use of enzalutamide for patients with metastatic castration-resistant prostate cancer (CRPC).Enzalutamide is an androgen receptor inhibitor that is taken orally once a day.It was...Related Biotechnology, ... [Published BioPortfolio - 6 hours ago]
First reported Sep 17 2014 - Updated 16 hours ago - 1 reports

Tokai Bags $97M For Prostate Cancer Drug in Upsized IPO

9/17/14 Follow @benthefidlerTokai Pharmaceuticals may be trying to break into an increasingly crowded field of prostate cancer drugs, but Wall Street investors clearly like its chances to make an impact.Cambridge, MA-based Tokai priced its IPO at $15 ... [Published Xconomy - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

AR-V7 linked to treatment resistance in castration-resistant prostate cancer

Detectable androgen receptor splice variant-7 messenger RNA in circulating tumor cells was associated with resistance to enzalutamide and abiraterone in men with castration-resistant prostate cancer, according to results of a prospective study.Emmanuel ... [Published Orthopedics Today - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Studies Help Refine Management of Prostate Cancer

Several studies reported at this year’s ASCO Annual Meeting address gray areas in the management of prostate cancer, according to Evan Y. Yu, MD , Associate Professor at the University of Washington and the Seattle Cancer Care Alliance. “In prostate cancer, ... [Published The ASCO Post - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

FDA Oks New Indication for the Use of XTANDI (enzalutamide) Capsules

Astellas Pharma and Medivation reported that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). According to ... [Published Individual.com - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Pre-chemotherapy indication for Xtandi in prostate cancer

The US FDA has approved the use of the oncology drug Xtandi prior to chemotherapy in patients with advanced prostate cancer.Xtandi (enzalutamide), an oral once-daily drug developed by Astellas and its partner Medivation, is now available in the US to ... [Published PMLive - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

West Coast Biotech Roundup: Gates, Orexigen, Medivation & More

The West Coast news of the past seven days was dominated by approvals. The FDA was responsible for two of them.In San Diego, Orexigen Therapeutics traveled a long, long road with its weight-loss drug Contrave, and finally saw the FDA’s green light. But ... [Published Xconomy - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Eagerly Awaited Expanded Xtandi Label Should Accelerate Sales

Medivation had already expanded its enzalutamide sales force to complement partner Astellas’ team ahead of getting a new indication for the earlier, pre-chemotherapy prostate cancer setting. The expanded label now paves the way for reps to drop in .. ... [Published BioPortfolio - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 3 reports

FDA Grants Expanded Indication for Enzalutamide Xtandi

Related Biotechnology, Pharmaceutical and Healthcare NewsThe oral androgen receptor inhibitor is now approved as first-line therapy for metastatic castration-resistant prostate cancer. FDA ApprovalsOriginal Article: FDA Grants Expanded Indication for ... [Published BioPortfolio - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 7 reports

FDA Grants Expanded Indication for Enzalutamide (Xtandi)

The US Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor enzalutamide ( Xtandi , Astellas/Medivation) as first-line therapy for metastatic castration-resistant prostate cancer (CRPC), the manufacturers said in a joint ... [Published General Medicine eJournal - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Androgen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancer

Pharmaceutical or surgical androgen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancer, and abiraterone acetate/prednisone, enzalutamide, or... ... [Published Cardiology News - Sep 11 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 3 reports

New breakthrough in prostate cancer treatment

A new study reported in the New England Journal of Medicine has revealed that testing of an abnormal protein in the blood could help in the identification of prostate cancer in case of men who cannot be helped by two new drugs.The name of this shortened ... [Published French Tribune - Sep 04 2014]

Quotes

NEXT ARTICLE More From BioPortfolio on "Enzalutamide may offer chemotherapy alternative in metastatic castration-resistant prostate cancer"
"This enables the use of an important therapy by patients with metastatic castration-resistant prostate cancer at all stages of their disease" said Dr Sef Kurstjens, chief medical officer of Astellas Pharma Inc. and president of Astellas Pharma Global Development, Inc
...endpoint of extending overall survival in men with mCRPC," said Michael M Morrissey, Ph D , president and chief executive officer of Exelixis. "We are grateful to the patients, physicians, nurses, caregivers, and other study team members who participated in the trial. We remain focused on the development program for cabozantinib beyond mCRPC, including the ongoing METEOR and CELESTIAL phase 3 pivotal trials, from which we expect top-line data in 2015 and 2017, respectively."
NEXT ARTICLE More From BioPortfolio on "FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer"

More Content

All (193) | News (155) | Reports (0) | Blogs (36) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
A new era in prostate cancer treatment [Published Irish Medical Times - 36 mins ago]
Prostate cancer drug therapy: ‘Don’t be afraid ... [Published City of Hope - 3 hours ago]
Enzalutamide may offer chemotherapy alternative... [Published BioPortfolio - 6 hours ago]
Enzalutamide may offer chemotherapy alternative... [Published Ecancer Medicalscience - 6 hours ago]
Xtandi Nabs New Prostate Cancer Indication [Published FDA News - 17 hours ago]
Tokai Bags $97M For Prostate Cancer Drug in Ups... [Published Xconomy - Sep 17 2014]
AR-V7 linked to treatment resistance in castrat... [Published Orthopedics Today - Sep 16 2014]
FDA News Roundup: Astellas, Sanofi Pasteur, Ore... [Published Pharmaceutical Online - Sep 16 2014]
Studies Help Refine Management of Prostate Cancer [Published The ASCO Post - Sep 15 2014]
Exelixis Announces Results from the COMET-1 Pha... [Published Pharmacy Choice - Sep 15 2014]
FDA Approves Use of Xtandi for Chemotherapy Nav... [Published BioPortfolio - Sep 15 2014]
FDA Oks New Indication for the Use of XTANDI (e... [Published Individual.com - Sep 15 2014]
FDA Approves Use of Xtandi for Chemotherapy Naï... [Published CancerConnect.com - Sep 15 2014]
West Coast Biotech Roundup: Gates, Orexigen, Me... [Published Xconomy - Sep 12 2014]
Pre-chemotherapy indication for Xtandi in prost... [Published PMLive - Sep 12 2014]
Eagerly Awaited Expanded Xtandi Label Should Ac... [Published BioPortfolio - Sep 11 2014]
FDA Grants Expanded Indication for Enzalutamide... [Published BioPortfolio - Sep 11 2014]
FDA Approves New Indication for the Use of Xtandi [Published BioPortfolio - Sep 11 2014]
FDA Grants Expanded Indication for Enzalutamide... [Published General Medicine eJournal - Sep 11 2014]
New ASCO Guideline for Castration-Resistant Pro... [Published American Journal of Public Health - Sep 11 2014]
FDA approves enzalutamide for chemo-naive metas... [Published Oncology Report - Sep 11 2014]
FDA approves Astellas and Medivation's expanded... [Published BioPortfolio - Sep 11 2014]
Androgen deprivation should be continued indefi... [Published Cardiology News - Sep 11 2014]
FDA approves prostate cancer drug from OHSU trial [Published Portland Business Journal - Sep 11 2014]
Pre-Chemo Enzalutamide Approved for Metastatic ... [Published Pharmacy Times - Sep 11 2014]
FDA approves Astellas and Medivation's expanded... [Published PBR - News - Sep 11 2014]
New indication for Astellas/Medivation’s Xtandi... [Published Pharma Letter - Sep 11 2014]
FDA approves new indication for Xtandi [Published Pharmafocus - Sep 11 2014]
FDA clears Xtandi for pre-chemo patients [Published Pharma Times - Sep 11 2014]
Astellas, Medivation's prostate cancer drug Xta... [Published FirstWord Pharma - Sep 11 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA approves Astellas and Medivation's expanded... [Published PBR - News - Sep 11 2014]
The US Food and Drug Administration (FDA) has granted approval to Astellas Pharma and Medivation's expanded use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). ...
Medivation and Astellas win expanded use for pr... [Published Tech Chronicles - Sep 11 2014]
San Francisco pharmaceutical company Medivation, and its partner Astellas Pharma, were celebrating Wednesday after winning federal permission to significantly expand the audience for their prostate cancer drug. The drug, Xtandi or enzalutamide, was first ...
U.S. FDA Approves New Indication for the Use of... [Published PR Newswire: Policy & Public Interest - Sep 10 2014]
TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI® (enzalutamide) ...
U.S. FDA Approves New Indication for the Use of... [Published Marketwire - Breaking News Releases - Sep 10 2014]
Approval Based on Improved Overall Survival, Delayed Time to Radiographic Progression and an Overall Positive Benefit-Risk Profile ...
AR-V7 and Resistance to Enzalutamide and Abirat... [Published The New England Journal of Medicine: Hematology ... - Sep 03 2014]
It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on androgen signaling. Owing to this new understanding, several drugs have recently emerged for the treatment of castration-resistant prostate ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Astellas Announces Marketing Approval in Japan ... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.